Spotlight on Rheumatology

Flavia Castelino, MD
Credits: 0.75 CME
Virtual “Escape Rheum”: A Case-Based Guide to Diagnosis and Management of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease
Flavia Castelino, MD
Integrity Continuing Education, Inc.

Virtual “Escape Rheum”: A Case-Based Guide to Diagnosis and Management of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 1, 2021
Expires: October 1, 2022
45 minutes to complete

Accredited By

Target Audience

This educational activity has been designed to meet the needs of rheumatology health care providers, including doctors, nurse practitioners, physician assistants, and other healthcare providers involved in the management of patients with CTD-PAH.

Learning Objectives

  • Recognize that patients with CTD are at increased risk for developing PAH.
  • Discuss the best practices for screening, diagnosis, classification, functional capacity classification, and utilization of echocardiography, and right heart catheterization (RHC) in CTD-PAH.
  • Review the clinical trial data, safety, efficacy, and side effect profiles of existing therapeutics for the management of PAH in the treatment of CTD-PAH based on evidence-based medicine and expert consensus.
  • Promote collaboration and care coordination across the multidisciplinary care team to optimize treatment in patients with CTD-PAH.
  • Identify communication strategies for promoting disease-understanding and shared decision-making among patients and caregivers to encourage them to take an active role in the disease management process.

Activity Description

Simulation Activity

Statement of Educational Need

Patients with rheumatic diseases are at higher risk of pulmonary arterial hypertension (PAH) secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This activity will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH. This educational activity will review the epidemiology, pathophysiology, and diagnostic strategies of PAH in patients with connective tissue diseases (CTD). Additionally, faculty will discuss which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team in managing these patients.

During this interactive online activity, learners listen to a brief lecture given by national faculty experts on diagnosis, staging, and treatment of patients with CTD-PAH. Learners will then enter an online escape room where they will be presented with a patient that they will work to diagnose and treat by answering clinical content questions to earn clues and lab results regarding their patient. Once they have treated the patient to the standard of care, the patient will be sent home with appropriate patient education and referrals to supportive care.

Faculty

Flavia Castelino, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Victor Tapson, MD
Professor of Medicine
Department of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Flavia Castelino, MD
No real or apparent conflicts of interest to disclose.

Victor Tapson, MD
Advisory Board: Actelion, Bayer, Johnson & Johnson, United Therapeutics
Research funding to institution: Actelion, Johnson & Johnson, United Therapeutics
Study Steering Committee: Bayer

The Integrity Continuing Education planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2021 through October 1, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Statement of Commercial Support

This program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson.

Disclaimer Statement

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 1, 2021
Expires: October 1, 2022
45 minutes to complete

Accredited By

Target Audience

This educational activity has been designed to meet the needs of rheumatology health care providers, including doctors, nurse practitioners, physician assistants, and other healthcare providers involved in the management of patients with CTD-PAH.

Learning Objectives

  • Recognize that patients with CTD are at increased risk for developing PAH.
  • Discuss the best practices for screening, diagnosis, classification, functional capacity classification, and utilization of echocardiography, and right heart catheterization (RHC) in CTD-PAH.
  • Review the clinical trial data, safety, efficacy, and side effect profiles of existing therapeutics for the management of PAH in the treatment of CTD-PAH based on evidence-based medicine and expert consensus.
  • Promote collaboration and care coordination across the multidisciplinary care team to optimize treatment in patients with CTD-PAH.
  • Identify communication strategies for promoting disease-understanding and shared decision-making among patients and caregivers to encourage them to take an active role in the disease management process.

Activity Description

Simulation Activity

Statement of Educational Need

Patients with rheumatic diseases are at higher risk of pulmonary arterial hypertension (PAH) secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This activity will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH. This educational activity will review the epidemiology, pathophysiology, and diagnostic strategies of PAH in patients with connective tissue diseases (CTD). Additionally, faculty will discuss which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team in managing these patients.

During this interactive online activity, learners listen to a brief lecture given by national faculty experts on diagnosis, staging, and treatment of patients with CTD-PAH. Learners will then enter an online escape room where they will be presented with a patient that they will work to diagnose and treat by answering clinical content questions to earn clues and lab results regarding their patient. Once they have treated the patient to the standard of care, the patient will be sent home with appropriate patient education and referrals to supportive care.

Faculty

Flavia Castelino, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Victor Tapson, MD
Professor of Medicine
Department of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Flavia Castelino, MD
No real or apparent conflicts of interest to disclose.

Victor Tapson, MD
Advisory Board: Actelion, Bayer, Johnson & Johnson, United Therapeutics
Research funding to institution: Actelion, Johnson & Johnson, United Therapeutics
Study Steering Committee: Bayer

The Integrity Continuing Education planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2021 through October 1, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Statement of Commercial Support

This program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson.

Disclaimer Statement

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Rheumatology Presentations

Sheetal Desai, MD, MSEd
0.75 AANP / AAPA / CME
Integrity Continuing Education, Inc.
A Light in the Darkness: Advances in Systemic Lupus Erythematosus

A Light in the Darkness: Advances in Systemic Lupus Erythematosus

Start

Activity Details

Free CME/AAPA/AANP
0.75 AMA PRA Category 1 Credit
0.75 Contact Hour(s)
Released: March 31, 2022
Expires: March 31, 2023
45 minutes to complete

Provider Statement

This CME activity for ACCME and AAPA credit is provided by Integrity Continuing Education, Inc.

This CE activity for AANP credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

Target Audience

This educational activity has been designed to meet the needs of rheumatologists, nurse practitioners, and physician assistants involved in the management of patients with Systemic Lupus Erythematosus (SLE).

Learning Objectives

  • DEMONSTRATE how to apply current evidence to the effective management of SLE
  • DESCRIBE current and emerging clinical evaluation tools and rating instruments used in clinical trials and/or clinical practice for patients with SLE
  • DISCUSS the utility of patient-centered shared decision-making and patient-reported outcomes in improving adherence and quality of life in patients with SLE
  • REVIEW mechanisms of action and outcomes data from recent clinical trials on new and emerging SLE targeted therapies

Activity Description

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder associated with significant morbidity and mortality, which impacts quality of life and life expectancy. Therapeutic strategies rely heavily on the use of corticosteroids to control inflammation; however, chronic use of these agents is responsible for much of the long-term damage accrual in SLE. Alongside corticosteroids, immunomodulators (hydroxychloroquine and vitamin D) should be maximized, and active disease should be controlled with immunosuppression or biologics when required. Due to the lack of standardized, objective clinical measures, rheumatology clinicians may delay escalation to an advanced therapy, causing many patients to linger unnecessarily on first-line therapies.

This activity will address evolving clinical evaluation tools and rating instruments that are necessary to fully understand clinical trial outcomes, integrate emerging treatments into clinical practice, and identify patients who would benefit most from these novel therapies.

Faculty

Sheetal Desai, MD, MSEd
Associate Professor
Department of Rheumatology
University of California, Irvine
Orange, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. and Global Education Group, for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CE/CME activities:

Sheetal Desai, MD, MSEd
Consulting: AstraZeneca, Aurinia Pharmaceuticals Inc., GlaxoSmithKline, Janssen Pharmaceuticals

Dave Mittman, DMSc (h.d.), PA, DFAAPA (Peer Reviewer) has no real or apparent conflicts of interest to report.

The following project managers/planners: Olivia Benevento, Stefani Chiarolanza, Lindsay Borvansky, Ashley Cann, Kristin Delisi, NP, Donna Fausak, Andrea Funk, Liddy Knight, and Patima Tanapat, PhD, reported that they or their spouses/life partners have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE/CME activity.

Accreditation

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education, Inc. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.75 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Physician Assistant Continuing Education (AAPA)
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid from 3/31/2022 to 3/31/2023. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-204547.

Instructions for Receiving Credit

There are no fees for participating and receiving CE/CME credit for this activity. During the period of March, 31, 2022 through March, 31, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Successful completion of the posttest is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.

Statement of Commercial Support

This activity is supported by an education grant from AstraZeneca Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME or AAPA accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about AANP accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/AAPA/AANP
0.75 AMA PRA Category 1 Credit
0.75 Contact Hour(s)
Released: March 31, 2022
Expires: March 31, 2023
45 minutes to complete

Provider Statement

This CME activity for ACCME and AAPA credit is provided by Integrity Continuing Education, Inc.

This CE activity for AANP credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

Target Audience

This educational activity has been designed to meet the needs of rheumatologists, nurse practitioners, and physician assistants involved in the management of patients with Systemic Lupus Erythematosus (SLE).

Learning Objectives

  • DEMONSTRATE how to apply current evidence to the effective management of SLE
  • DESCRIBE current and emerging clinical evaluation tools and rating instruments used in clinical trials and/or clinical practice for patients with SLE
  • DISCUSS the utility of patient-centered shared decision-making and patient-reported outcomes in improving adherence and quality of life in patients with SLE
  • REVIEW mechanisms of action and outcomes data from recent clinical trials on new and emerging SLE targeted therapies

Activity Description

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder associated with significant morbidity and mortality, which impacts quality of life and life expectancy. Therapeutic strategies rely heavily on the use of corticosteroids to control inflammation; however, chronic use of these agents is responsible for much of the long-term damage accrual in SLE. Alongside corticosteroids, immunomodulators (hydroxychloroquine and vitamin D) should be maximized, and active disease should be controlled with immunosuppression or biologics when required. Due to the lack of standardized, objective clinical measures, rheumatology clinicians may delay escalation to an advanced therapy, causing many patients to linger unnecessarily on first-line therapies.

This activity will address evolving clinical evaluation tools and rating instruments that are necessary to fully understand clinical trial outcomes, integrate emerging treatments into clinical practice, and identify patients who would benefit most from these novel therapies.

Faculty

Sheetal Desai, MD, MSEd
Associate Professor
Department of Rheumatology
University of California, Irvine
Orange, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. and Global Education Group, for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CE/CME activities:

Sheetal Desai, MD, MSEd
Consulting: AstraZeneca, Aurinia Pharmaceuticals Inc., GlaxoSmithKline, Janssen Pharmaceuticals

Dave Mittman, DMSc (h.d.), PA, DFAAPA (Peer Reviewer) has no real or apparent conflicts of interest to report.

The following project managers/planners: Olivia Benevento, Stefani Chiarolanza, Lindsay Borvansky, Ashley Cann, Kristin Delisi, NP, Donna Fausak, Andrea Funk, Liddy Knight, and Patima Tanapat, PhD, reported that they or their spouses/life partners have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE/CME activity.

Accreditation

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education, Inc. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.75 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Physician Assistant Continuing Education (AAPA)
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid from 3/31/2022 to 3/31/2023. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-204547.

Instructions for Receiving Credit

There are no fees for participating and receiving CE/CME credit for this activity. During the period of March, 31, 2022 through March, 31, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Successful completion of the posttest is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.

Statement of Commercial Support

This activity is supported by an education grant from AstraZeneca Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME or AAPA accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about AANP accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

Flavia Castelino, MD
0.75 CME
Integrity Continuing Education, Inc.
Virtual “Escape Rheum”: A Case-Based Guide to Diagnosis and Management of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease

Virtual “Escape Rheum”: A Case-Based Guide to Diagnosis and Management of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 1, 2021
Expires: October 1, 2022
45 minutes to complete

Accredited By

Target Audience

This educational activity has been designed to meet the needs of rheumatology health care providers, including doctors, nurse practitioners, physician assistants, and other healthcare providers involved in the management of patients with CTD-PAH.

Learning Objectives

  • Recognize that patients with CTD are at increased risk for developing PAH.
  • Discuss the best practices for screening, diagnosis, classification, functional capacity classification, and utilization of echocardiography, and right heart catheterization (RHC) in CTD-PAH.
  • Review the clinical trial data, safety, efficacy, and side effect profiles of existing therapeutics for the management of PAH in the treatment of CTD-PAH based on evidence-based medicine and expert consensus.
  • Promote collaboration and care coordination across the multidisciplinary care team to optimize treatment in patients with CTD-PAH.
  • Identify communication strategies for promoting disease-understanding and shared decision-making among patients and caregivers to encourage them to take an active role in the disease management process.

Activity Description

Simulation Activity

Statement of Educational Need

Patients with rheumatic diseases are at higher risk of pulmonary arterial hypertension (PAH) secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This activity will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH. This educational activity will review the epidemiology, pathophysiology, and diagnostic strategies of PAH in patients with connective tissue diseases (CTD). Additionally, faculty will discuss which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team in managing these patients.

During this interactive online activity, learners listen to a brief lecture given by national faculty experts on diagnosis, staging, and treatment of patients with CTD-PAH. Learners will then enter an online escape room where they will be presented with a patient that they will work to diagnose and treat by answering clinical content questions to earn clues and lab results regarding their patient. Once they have treated the patient to the standard of care, the patient will be sent home with appropriate patient education and referrals to supportive care.

Faculty

Flavia Castelino, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Victor Tapson, MD
Professor of Medicine
Department of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Flavia Castelino, MD
No real or apparent conflicts of interest to disclose.

Victor Tapson, MD
Advisory Board: Actelion, Bayer, Johnson & Johnson, United Therapeutics
Research funding to institution: Actelion, Johnson & Johnson, United Therapeutics
Study Steering Committee: Bayer

The Integrity Continuing Education planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2021 through October 1, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Statement of Commercial Support

This program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson.

Disclaimer Statement

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 1, 2021
Expires: October 1, 2022
45 minutes to complete

Accredited By

Target Audience

This educational activity has been designed to meet the needs of rheumatology health care providers, including doctors, nurse practitioners, physician assistants, and other healthcare providers involved in the management of patients with CTD-PAH.

Learning Objectives

  • Recognize that patients with CTD are at increased risk for developing PAH.
  • Discuss the best practices for screening, diagnosis, classification, functional capacity classification, and utilization of echocardiography, and right heart catheterization (RHC) in CTD-PAH.
  • Review the clinical trial data, safety, efficacy, and side effect profiles of existing therapeutics for the management of PAH in the treatment of CTD-PAH based on evidence-based medicine and expert consensus.
  • Promote collaboration and care coordination across the multidisciplinary care team to optimize treatment in patients with CTD-PAH.
  • Identify communication strategies for promoting disease-understanding and shared decision-making among patients and caregivers to encourage them to take an active role in the disease management process.

Activity Description

Simulation Activity

Statement of Educational Need

Patients with rheumatic diseases are at higher risk of pulmonary arterial hypertension (PAH) secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This activity will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH. This educational activity will review the epidemiology, pathophysiology, and diagnostic strategies of PAH in patients with connective tissue diseases (CTD). Additionally, faculty will discuss which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team in managing these patients.

During this interactive online activity, learners listen to a brief lecture given by national faculty experts on diagnosis, staging, and treatment of patients with CTD-PAH. Learners will then enter an online escape room where they will be presented with a patient that they will work to diagnose and treat by answering clinical content questions to earn clues and lab results regarding their patient. Once they have treated the patient to the standard of care, the patient will be sent home with appropriate patient education and referrals to supportive care.

Faculty

Flavia Castelino, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Victor Tapson, MD
Professor of Medicine
Department of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Flavia Castelino, MD
No real or apparent conflicts of interest to disclose.

Victor Tapson, MD
Advisory Board: Actelion, Bayer, Johnson & Johnson, United Therapeutics
Research funding to institution: Actelion, Johnson & Johnson, United Therapeutics
Study Steering Committee: Bayer

The Integrity Continuing Education planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2021 through October 1, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Statement of Commercial Support

This program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson.

Disclaimer Statement

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Elizabeth R. Volkmann, MD, MS
1.00 CME
Vindico Medical Education
SSc-ILD Podcast Series: Clinical Updates to Manage a Rare Lung Condition

SSc-ILD Podcast Series: Clinical Updates to Manage a Rare Lung Condition

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, dermatologists, and other health care professionals involved in the management of patients with systemic sclerosis-associated interstitial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Examine the prevalence, risk factors, and disease course of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • Evaluate strategies to ensure timely screening and monitoring for early diagnosis of patients with SSc-ILD.
  • Review treatment options based on clinical evidence and expert guidelines.
  • Assess communication strategies to help facilitate effective management, self-care and adherence in patients with SSc-ILD.

Activity Description

In this 4-part podcast series, expert faculty review best practices for the screening and diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). They will also review the current and emerging therapies and the clinical evidence supporting their use in SSc-ILD.

Statement of Educational Need

Systemic sclerosis (SSc) is a rare multisystem autoimmune disorder with estimated incidence and prevalence estimates in the United States of 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively. In SSc, sclerosis of the skin, vasculopathy, and damage to internal organs including the lungs develop results from a complex interplay between vascular injury, fibrotic processes and immunological pathways. Lung involvement is the leading cause of SSc-associated death. Lung fibrosis develops in 80% of patients, and 25% to 30% develop progressive interstitial lung disease (ILD), leading to a 10-year mortality of up to 40% in those affected. It is thus crucial that clinicians can recognize and diagnose SSc-associated ILD (SSc-ILD) early to initiate appropriate therapy in a timely manner. Clinicians must also be abreast of the most recent treatment guidelines and the current and emerging therapies for SSc-ILD so they can plan optimal treatment plans for their patients.

Agenda

Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth Volkmann and Kevin Flaherty

Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth Volkmann and Kristin Highland

Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth Volkmann and Kevin Flaherty

Improving Adherence: Patient Engagement and Education With Drs. Elizabeth Volkmann and Kristin Highland

Activity Chair

Elizabeth R. Volkmann, MD, MS
Associate Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Kadmon

Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Disclosure: Consulting Fee: Arrowhead, AstraZeneca, Bellerophon, Boehringer Ingelheim, DevPro, FibroGen, Horizon, Lupin, Pliant, Polarean, PureHealth, PureTech, Respivant, Shionogi, Sun, United Therapeutics
Contracted Research: Boehringer Ingelheim


Kristin B. Highland, MD, MSCR
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Actelion, Bayer, Boehringer Ingelheim, United Therapeutics
Contracted Research: Acceleron, Actelion, Bayer, Boehringer Ingelheim, Gossamer Bio, United Therapeutics, Viela Bio

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, dermatologists, and other health care professionals involved in the management of patients with systemic sclerosis-associated interstitial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Examine the prevalence, risk factors, and disease course of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • Evaluate strategies to ensure timely screening and monitoring for early diagnosis of patients with SSc-ILD.
  • Review treatment options based on clinical evidence and expert guidelines.
  • Assess communication strategies to help facilitate effective management, self-care and adherence in patients with SSc-ILD.

Activity Description

In this 4-part podcast series, expert faculty review best practices for the screening and diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). They will also review the current and emerging therapies and the clinical evidence supporting their use in SSc-ILD.

Statement of Educational Need

Systemic sclerosis (SSc) is a rare multisystem autoimmune disorder with estimated incidence and prevalence estimates in the United States of 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively. In SSc, sclerosis of the skin, vasculopathy, and damage to internal organs including the lungs develop results from a complex interplay between vascular injury, fibrotic processes and immunological pathways. Lung involvement is the leading cause of SSc-associated death. Lung fibrosis develops in 80% of patients, and 25% to 30% develop progressive interstitial lung disease (ILD), leading to a 10-year mortality of up to 40% in those affected. It is thus crucial that clinicians can recognize and diagnose SSc-associated ILD (SSc-ILD) early to initiate appropriate therapy in a timely manner. Clinicians must also be abreast of the most recent treatment guidelines and the current and emerging therapies for SSc-ILD so they can plan optimal treatment plans for their patients.

Agenda

Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth Volkmann and Kevin Flaherty

Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth Volkmann and Kristin Highland

Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth Volkmann and Kevin Flaherty

Improving Adherence: Patient Engagement and Education With Drs. Elizabeth Volkmann and Kristin Highland

Activity Chair

Elizabeth R. Volkmann, MD, MS
Associate Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Kadmon

Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Disclosure: Consulting Fee: Arrowhead, AstraZeneca, Bellerophon, Boehringer Ingelheim, DevPro, FibroGen, Horizon, Lupin, Pliant, Polarean, PureHealth, PureTech, Respivant, Shionogi, Sun, United Therapeutics
Contracted Research: Boehringer Ingelheim


Kristin B. Highland, MD, MSCR
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Actelion, Bayer, Boehringer Ingelheim, United Therapeutics
Contracted Research: Acceleron, Actelion, Bayer, Boehringer Ingelheim, Gossamer Bio, United Therapeutics, Viela Bio

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Atul A. Deodhar, MD, MRCP, FACR, FACP
1.00 AANP / CME
AKH Inc., Advancing Knowledge in Healthcare
PsA+COVID-19: Augmented Reality and Patient Engagement in the Treatment of Psoriatic Arthritis

PsA+COVID-19: Augmented Reality and Patient Engagement in the Treatment of Psoriatic Arthritis

Start

Activity Details

Free CME/AANP
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 21, 2021
Expires: June 21, 2022
60 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with psoriatic arthritis (PsA) can benefit from participation in this education.

Learning Objectives

As a result of participation in this initiative, participants will increase their ability to:

  1. Use augmented reality (AR) apps for providers and patients on mechanisms of action (MOAs) of therapies for treatment of PsA.
  2. Discuss effectiveness and safety of conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  3. Apply evolving recommendations and clinical practice guidelines related to COVID-19 infection and vaccination to providing care to patients with PsA.
  4. Inform patients with PsA about the impact of their disease and the benefits and risks of medications in the context of COVID-19 infection and vaccination when making shared decisions about treatment plan and treatment modifications.

Activity Description

COVID-19 has impacted PsA patient care in many ways, particularly for patients with multiple comorbidities. This interactive activity reviews clinical practice guidelines addressing COVID-19 infection and vaccination that are relevant to patients with PsA, highlights effectiveness and safety of therapies for PsA, and offers a self-directed experience of building and solving patient cases to learn from making decisions and receiving immediate feedback. This activity also incorporates the patient perspective, a skill-oriented presentation on engaging patients in shared decision making, decision aids, and a demonstration of an augmented reality (AR) app on PsA for healthcare providers and patients.

Please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device to gain the most benefit from participation in this activity. You may use this QR code or search for it in Google Play or the App Store.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Agenda

  1. Providing Psoriatic Arthritis Care During the COVID-19 Pandemic
  2. Using Shared Decision Making to Engage Patients With Psoriatic Arthritis to Clarify Treatment Goals in the Context of COVID-19
  3. Demonstration of Augmented Reality App for Providers and Patients
  4. Personalized Patient Cases

Faculty

Atul A. Deodhar, MD, MRCP, FACR, FACP
Professor of Medicine,
Medical Director of Rheumatology Clinics,
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon


Richard Martin, MD, MA
Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
Grand Rapids, Michigan


David Kramer
Patient Presenter

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

  • Planners (Forefront Collaborative): Leah Johnson and Marianna Shershneva, MD, PhD
  • Planners (Faculty): Linda Grinnell-Merrick, MS, NP-BC
  • Patient Presenter: David Kramer
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

Faculty Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP

  • Consultant: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB
  • Speaker: Eli Lilly, Janssen, Novartis, Pfizer
  • Independent contractor (including contracted research): AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB

Faculty Presenter: Richard Martin, MD, MA

  • Contracted Research/Current Clinical Trials: AbbVie, Eli Lilly

Faculty Planner: Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer, Sanofi

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Free CME/AANP
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 21, 2021
Expires: June 21, 2022
60 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with psoriatic arthritis (PsA) can benefit from participation in this education.

Learning Objectives

As a result of participation in this initiative, participants will increase their ability to:

  1. Use augmented reality (AR) apps for providers and patients on mechanisms of action (MOAs) of therapies for treatment of PsA.
  2. Discuss effectiveness and safety of conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  3. Apply evolving recommendations and clinical practice guidelines related to COVID-19 infection and vaccination to providing care to patients with PsA.
  4. Inform patients with PsA about the impact of their disease and the benefits and risks of medications in the context of COVID-19 infection and vaccination when making shared decisions about treatment plan and treatment modifications.

Activity Description

COVID-19 has impacted PsA patient care in many ways, particularly for patients with multiple comorbidities. This interactive activity reviews clinical practice guidelines addressing COVID-19 infection and vaccination that are relevant to patients with PsA, highlights effectiveness and safety of therapies for PsA, and offers a self-directed experience of building and solving patient cases to learn from making decisions and receiving immediate feedback. This activity also incorporates the patient perspective, a skill-oriented presentation on engaging patients in shared decision making, decision aids, and a demonstration of an augmented reality (AR) app on PsA for healthcare providers and patients.

Please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device to gain the most benefit from participation in this activity. You may use this QR code or search for it in Google Play or the App Store.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Agenda

  1. Providing Psoriatic Arthritis Care During the COVID-19 Pandemic
  2. Using Shared Decision Making to Engage Patients With Psoriatic Arthritis to Clarify Treatment Goals in the Context of COVID-19
  3. Demonstration of Augmented Reality App for Providers and Patients
  4. Personalized Patient Cases

Faculty

Atul A. Deodhar, MD, MRCP, FACR, FACP
Professor of Medicine,
Medical Director of Rheumatology Clinics,
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon


Richard Martin, MD, MA
Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
Grand Rapids, Michigan


David Kramer
Patient Presenter

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

  • Planners (Forefront Collaborative): Leah Johnson and Marianna Shershneva, MD, PhD
  • Planners (Faculty): Linda Grinnell-Merrick, MS, NP-BC
  • Patient Presenter: David Kramer
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

Faculty Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP

  • Consultant: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB
  • Speaker: Eli Lilly, Janssen, Novartis, Pfizer
  • Independent contractor (including contracted research): AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB

Faculty Presenter: Richard Martin, MD, MA

  • Contracted Research/Current Clinical Trials: AbbVie, Eli Lilly

Faculty Planner: Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer, Sanofi

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.